Nurix Therapeutics (NRIX) Stifel Virtual Immunology and Inflammation Forum summary

BTK degradation and competitive differentiation

• BTK is a versatile target expressed on multiple immune cell types, with disease-specific amplification making it relevant across various autoimmune diseases.

• Bexobrutideg degrades BTK, removing both enzymatic and scaffolding functions, unlike kinase inhibitors that only block enzymatic activity.

• Degradation approach shows efficacy in patients resistant to kinase inhibitors, suggesting broader therapeutic potential.

• Bexobrutideg demonstrates 10–100-fold greater potency in immune cell assays compared to leading BTK inhibitors.

Clinical development and formulation updates

• Clinical proof-of-concept data in CLL patients with autoimmune hemolytic anemia is expected in 2026, with hemoglobin levels as a key efficacy measure.

• A new tablet formulation is under multiple ascending dose study, offering broader dosing and patient-friendly features.

• IND filing for an autoimmune indication is targeted for 2026, leveraging data from both capsule and tablet formulations.

Strategic outlook and partnerships

• Stepwise development is planned, with potential for partnerships in larger indications but current efforts are self-funded.

• Investigational programs aim to develop new BTK degraders with enhanced selectivity, potency, and PK profiles.

• New molecular entities could enable differentiated pricing and development paths, especially in non-oncology indications.